Filing Details
- Accession Number:
- 0000950170-23-043973
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-22 18:24:58
- Reporting Period:
- 2023-08-21
- Accepted Time:
- 2023-08-22 18:24:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1817838 | Douglas Joseph Lyon | C/O Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park CA 94025 | Chief Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-08-21 | 3,755 | $8.27 | 8,887 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2023-08-21 | 833 | $11.35 | 9,720 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-08-21 | 4,588 | $31.19 | 5,132 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Disposition | 2023-08-21 | 3,755 | $0.00 | 3,755 | $8.27 |
Common Stock | Stock option (right to buy) | Disposition | 2023-08-21 | 833 | $0.00 | 833 | $11.35 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2027-02-10 | No | 4 | M | Direct | |
64,167 | 2029-02-08 | No | 4 | M | Direct |
Footnotes
- Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023 and 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- The sales reported in this Form 4 were affected pursuant to Rule 144.
- Fully exercisable.